Skip to main content

Advertisement

Featured article: Epigenetic synthetic lethality approaches in cancer therapy

With the introduction of the first synthetic lethal drug, interest in this topic has grown rapidly. In this review on epigenetic-related synthetic lethal mechanisms, the authors focus on synthetic lethality between epigenetic mutations and epigenetic inhibitors, epigenetic mutations and non-epigenetic inhibitors, and oncogene mutations and epigenetic inhibitors.

Articles

2019
Pollution and Epigenetics
First published: 21 January 2019
Edited by: Steven Gray and Wim Vanden Berghe

2018
Cross-journal collection
Pluripotent Stem Cells
First published: 19 July 2018

2016

Cross-journal collection
Asthma Genetics and Epigenetics
Collection first published: 19 October 2016

Epigenetic Drugs
Edited by: Lucia Altucci & Marianne Rots
First published: 23 May 2016

2015

Breakthroughs in clinical epigenetics
Edited by: Marianne Rots
First published: 1 March 2015

 

Featured Collection

New Content Item © Credit: David Holt (CC BY 2.0)The first articles in our thematic series on Pollution and Epigenetics have published. The Editors are still accepting submissions to the series for the next couple of months.

Submit your research on pollution and epigenetics today.

Graphical Abstracts Now Available

Authors submitting to Clinical Epigenetics now have the option to include a Graphical Abstract when they submit their manuscript.  An image may be uploaded during submission which, together with the article title and abstract text, should provide the reader with a visual description of the topic covered in the article. Graphical abstracts will appear in the HTML version of the article (but not in the PDF version). Instructions for including graphical abstracts is available in the Submission Guidelines for the appropriate article types.

Upcoming Meetings

3rd Epigenetics and Bioengineering Conference (EpiBio 2019

September 12-14, 2019 in Barcelona, Spain at the Hotel Barcelona Center

If you'd like to meet or speak with the Editors-in-Chief, both of whom will be attending this meeting, please contact Marianne Rots directly at m.g.rots@umcg.nl. 

Editors-in-Chief

Lucia AltucciUniversità degli Studi della Campania, Italy
Marianne RotsUniversity Medical Center Groningen, Netherlands  

Aims & Scope

Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections:

  • Aging and development epigenetics
  • Allergy, immunology, and pathogen epigenetics
  • Cancer epigenetics and diagnostics
  • Cardiovascular epigenetics
  • Endocrinology and metabolic epigenetics
  • Environmental epigenetics
  • Epigenetic biomarkers
  • Epigenetic technologies
  • Epigenetic therapies and clinical trials
  • Innovative therapies
  • Lifestyle epigenetics
  • Neurology and psychiatry epigenetics
  • Regenerative medicine
  • Reproductive and transgenerational epigenetics

For more information on the section aims and scope visit our section information page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here. Please note our new policy regarding submissions involving RNA in our instructions to authors.

Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications

Differential RNA expression levels (coding or non-coding) or RNA modifications cannot be considered as part of epigenetics, and this includes levels of the RNA modifying enzymes or readers.

The fact that non-coding RNAs might affect other genes at their RNA level classifies these molecules as post-transcriptional gene expression regulators. Although modification of RNAs resembles modifications of DNA or histone proteins, so do post-translational modifications of various proteins. As such, RNAs modifiers as a class of regulators are not different from protein-modifiers, which also are not considered part of epigenetics per se. 

For manuscripts on non-coding RNAs to be considered for publication in Clinical Epigenetics, the authors must provide at least one of the following:

  • data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes); or
  • insights on the mechanism of action of the non-coding RNA on the functioning of the DNA; or
  • insights in mitotic stability of the RNA-induced effect.

Archival Content

In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.

Advertisement

Annual Journal Metrics

Advertisement